Public record
The Texas House Research Organization’s 2005 analysis of HB 984 includes Kevin McMahon of Diabetech in the witness record supporting legislation on diabetes self-care in schools. It is a dated public record of participation in the policy discussion.
The record is evidence of advocacy and engagement. It does not establish that Kevin alone wrote the law, caused its passage, or determined every subsequent implementation decision.
Connection to the operating work
Kevin’s professional work involved children, families, school-related care, remote monitoring, physician participation, and reimbursement. The policy environment affected where and how a service could function. His career narrative includes advocacy around recognition of the home as a telemedicine setting and practical access to remote support.
The strongest linked public source here concerns the school self-care legislation. Broader causal claims about telemedicine policy are not inferred from that source.
Product and service relevance
Policy and reimbursement can shape a product’s actual usefulness. A remote technology may be technically feasible while the service model still depends on clinician participation, acceptable care settings, and payer arrangements. Kevin’s experience includes working across those constraints rather than considering them only after development.
This record adds public-policy participation to the broader account of product, clinical, and commercial collaboration. It complements the payer-program and care-delivery records without substituting for their distinct evidence.
Sources and record basis
- Government recordTexas House Research Organization · HB 984 bill analysis, 2005
Lists Kevin McMahon of Diabetech in the witness record supporting diabetes self-care legislation. It documents participation rather than sole responsibility for policy change.
- Government recordTexas State Health Plan 2011–2016
Includes GlucoMON as an example of wireless patient monitoring. This supports public recognition of the technology, not all commercial or clinical claims.